<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1211246211
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lotemax
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LOTEPREDNOL ETABONATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Multidose container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        44
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Bausch &amp; Lomb, Incorporated" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Bausch & Lomb, Incorporated
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Bausch & Lomb, Incorporated
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lotemax is an eye drop suspension.</p><p>Sometimes the eye may become inflamed (red and painful). Loteprednol etabonate is one of a group of medicines called corticosteroids. It acts by reducing inflammation and eases the symptoms. Because it is used in low doses directly where it is needed, its action is only at this place.</p><p>Lotemax is used for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.</p><p>Lotemax is also used for the treatment of inflammation of the eye following ocular surgery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Lotemax:</strong></p><p>- if you are allergic to the active substance (loteprednol) or any of the other ingredients of this medicine (listed in section 6).</p><p>- if you have been allergic to any other corticosteroid.</p><p>- if you have eye diseases caused by viruses such as herpes simplex, vaccinia, and varicella.</p><p>- if you have eye diseases caused by mycobacterium and fungi.</p><p><strong>Warnings and precautions</strong></p><p>Tell your doctor if you already have glaucoma.</p><p>Tell your doctor if pain develops, or if redness, itching, or inflammation gets worse. See your doctor if your symptoms do not get better within 2 days. He/she may want to re-evaluate your condition.</p><p>You should not use Lotemax longer than 10 days without having the pressure in your eye checked by your doctor.</p><p>Long-term use of Lotemax or other eye drops that contain steroids, may result in glaucoma or raised pressure in the eye, which can cause damage to the optic nerve, problems with vision, and cataracts. Long-term use of Lotemax or other eye drops that contain steroids, may lower your ability to fight infections and may increase your chance of getting an eye infection including herpes simplex.</p><p>Using steroid eye drops like Lotemax may make viral diseases of the eye worse and last longer. The use of steroid eye drops after cataract surgery may delay healing and increase the incidence of bleb formation.</p><p><u>Contact lens usage</u></p><p>You should not wear contact lenses when using Lotemax.</p><p><strong>Other medicines and Lotemax</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>It is possible that you may still receive Lotemax, but it is also possible that an alternative may be used. Lotemax should not be used when breast-feeding.</p><p><strong>Driving and using machines</strong></p><p>Eye drops can cause your vision to be blurred. Do not drive or use machines until your vision is clear. No studies have been performed on the ability to drive and use machines after instillation.</p><p><strong>Lotemax contains benzalkonium chloride</strong></p><p>The preservative Benzalkonium chloride may cause eye irritation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><em><u>Uses after Surgery</u></em></p><p>The recommended dose for adults and elderly is one to two drops of Lotemax into conjunctival sack of the affected eye(s) four times daily.</p><p>Treatment with Lotemax normally begins 24 hours after surgery and continues for two weeks.</p><p><em><u>Uses in other Steroid Responsive Disease</u>:</em></p><p>Apply one to two drops of LOTEMAX into the conjunctival sac of the affected eye(s) four times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour. See your doctor if your symptoms do not get better within 2 days (see &ldquo;Warning and precautions&rdquo;).</p><p><strong>Use in adults</strong></p><p>&bull; Shake Lotemax well before using.</p><p>&bull;&nbsp;Look upwards and gently pull down the lower eyelid of the affected eye(s).</p><p>&bull; Apply one to two drops of Lotemax into the gap between your eyeball and eyelid, four times a day or as directed by your doctor.</p><p>&bull; Do not allow the tip of the dropper to touch any surface because this may contaminate the medicine.</p><p>&bull;&nbsp;The bottle should be closed immediately after use.</p><p>&bull;&nbsp;Your doctor will tell you how long your treatment with Lotemax will last.</p><p>&bull;&nbsp;Do not stop treatment without talking with your doctor.</p><p><strong>Use in children and adolescents</strong></p><p>Lotemax should not be used in children and adolescents until further data becomes available.</p><p><strong>If you use more Lotemax than you should</strong></p><p>Tell your doctor or a pharmacist.</p><p><strong>If you forget to use Lotemax</strong></p><p>Do not take a double dose to make up for a forgotten dose. Wait until the next dose and then continue as before.</p><p><strong>If you stop using Lotemax</strong></p><p>Always use this medicine exactly as your doctor has told you. Do not stop using Lotemax without speaking to your doctor first.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects,</p><p>posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.</p><p>Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2%-0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, conjunctiva swelling, eye discharge, dry eyes, tearing, foreign body sensation in eyes, ocular itching, conjunctiva redness, and light sensitivity. Other ocular adverse reactions occurring in less than 5% of patients include inflammation of conjunctiva, corneal abnormalities, eyelid erythema, inflammation of cornea and conjunctiva, ocular irritation/pain/discomfort, papillae, and inflammation of uvea. Some of these events were similar to the underlying ocular disease being studied.</p><p>Non-ocular adverse reactions occurred in less than 15% of patients. These include headache, runny nose and inflammation of the throat.</p><p><strong>Reporting of side effects</strong></p><p>Healthcare professionals are asked to report any suspected adverse reactions</p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C. DO NOT FREEZE. KEEP OUT OF REACH OF CHILDREN.</p><p><strong>Discard any unused contents 28 days after first opening the bottle.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active ingredient is Loteprednol Etabonate. Each ml contains 5 mg (0.5%) Loteprednol Etabonate.</p><p>- The other ingredients are Disodium Edetate, Glycerol, Povidone, Purified Water and Tyloxapol.</p><p>- Benzalkonium Chloride (0.01%) is added as a preservative.</p><p>- Sodium Hydroxide and/or Hydrochloric Acid are added to adjust the pH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lotemax is a milky-white eye-drops suspension.
Lotemax is available in bottles containing 5 ml of the medicine.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bausch and Lomb Incorporated</p><p>Tampa, Florida 33637</p><p>USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لوتماكس هو قطرات للعين، مستعلق.</p><p dir="RTL">في بعض الأحيان قد تصبح العين ملتهبة (حمراء ومؤلمة). ينتمي لوتيبريدنول ايتابونات إلى مجموعة من الأدوية تعرف باسم كورتيكوستيرويدات والتي تعمل على الحد من الالتهاب والتقليل من ظهور الأعراض؛ ونظرا لأنها تستخدم بجرعات قليلة وبشكل مباشر عند الحاجة، فإن مفعولها يكون مقصورا على مكان الاستخدام فقط.</p><p dir="RTL">يوصف لوتماكس لمداواة التهابات العين التي تؤثر فيها الستيرويدات، في أجزاء العين التالية:</p><p dir="RTL">ملتحمة الجفن وملتحمة البصيلة، القرنية، الشطر الأمامي من العين مثل حساسية التهاب الملتحمة ، بثور حب الشباب، التهابات القرنية (المنقطة السطحية)، هربس التهاب القرنية النطاقي ، التهاب القزحية، التهاب الجسم الهدبي؛ في علاج بعض أنواع التهابات ملتحمة العين عندما يكون الخطر الملازم لاستعمال الكورتيكوستيرويدات مقبولا لتخفيف الورم والالتهاب</p><p dir="RTL">يتم وصف دواء<strong> </strong>لوتماكس لعلاج الالتهاب الذي يلي إجراء عملية جراحية في العين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجب استخدام لوتماكس :</strong></p><p dir="RTL">- إذا كان المريض يعاني من حساسية تجاه المادة الفعالة (لوتيبريدنول) أو أي من مكونات الدواء الآخرى (المدرجة في القسم رقم 6).</p><p dir="RTL">- إذا كان المريض يعاني من التحسس لأي من الكورتيكوسترويدات الأخرى.</p><p dir="RTL">-&nbsp;إذا كان المريض يعاني من أمراض العيون الناتجة عن الإصابة بالفيروسات مثل فيروس الهربس البسيط وفيروس الوقس وفيروس جديري الماء.</p><p dir="RTL">-&nbsp;إذا كان المريض يعاني من أمراض العيون الناجمة عن البكتريا الفطرية والفطريات.</p><p dir="RTL"><strong>التحذيرات والإحتياطات:</strong></p><p dir="RTL">- أخبر طبيبك إذا كنت تعاني بالفعل من مرض المياه الزرقاء.</p><p dir="RTL">- أخبر طبيبك إذا شعرت بإزدياد الألم، أو تفاقم الاحمرار، أو الحكة، أو الالتهاب.</p><p dir="RTL">- استشر طبيبك إذا لم تتحسن الأعراض في غضون يومين فقد تحتاج إلى إعادة فحص للحالة.</p><p dir="RTL">- يجب ألا تقوم بإستخدام دواء لوتماكس لأكثر من 10 أيام بدون فحص ضغط العين بواسطة الطبيب.</p><p dir="RTL">- قد يؤدي استخدام لوتماكس لفترة طويلة أو أي من قطرات العين التي تحتوي على الستيرويد إلى الإصابة بمرض المياه الزرقاء أو ارتفاع ضغط العين، مما قد يؤدي الى تلف العصب البصري ومشكلات في الرؤية واعتام في عدسة العين.</p><p dir="RTL">-&nbsp;قد يؤدي استخدام لوتماكس لفترة طويلة أو أي من قطرات العين التي تحتوي على مادة الستيرويدات إلى تقليل قدرتك على مقاومة العدوى، وزيادة فرصة الاصابة بعدوى العين بما يشمل فيروس الهربس البسيط.</p><p dir="RTL">-&nbsp;قد يؤدي استخدام قطرات العين التي تحتوي على مادة الستيرويد مثل<strong> </strong>لوتماكس إلى تفاقم حالة الأمراض الفيروسية بالعين وامتدادها لفترة أطول.</p><p dir="RTL">-&nbsp;استخدام قطرات العين التي تحتوي على مادة الستيرويد بعد جراحة العدسة المعتمة الى تأخير الشفاء وزيادة فرصة الإصابة بالقروح.</p><p dir="RTL"><strong>استخدام العدسات اللاصقة</strong></p><p dir="RTL">-&nbsp;يجب عدم ارتداء العدسات اللاصقة أثناء استخدام لوتماكس.</p><p dir="RTL"><strong>الأدوية الأخرى ولوتماكس</strong></p><p dir="RTL">-&nbsp;أبلغ الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملا أو مرضعة أو تعتقدين أنكِ حاملا أو تخططين للحمل استشيري الطبيب أو الصيدلي قبل استخدام لوتماكس.</p><p dir="RTL">يمكنك الاستمرار في استخدام لوتماكس، كما يمكنك إستخدام بديل آخر.</p><p dir="RTL">يجب ألا تقومي بإستخدام لوتماكس<strong> </strong>في فترة الرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">يمكن أن تتسبب قطرات العين في ضبابية الرؤية ولذا لا تقود السيارة أو تستخدم الآلات حتى تصبح رؤيتك واضحة.</p><p dir="RTL">لم يتم إجراء أي دراسات حول القدرة على القيادة واستخدام الآلات بعد التقطير.</p><p dir="RTL"><strong>يحتوي لوتماكس على مادة كلوريد البنزالكونيوم</strong></p><p dir="RTL">قد تتسبب المادة الحافظة كلوريد البنزالكونيوم في حدوث تهيج بالعين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما استخدم هذا الدواء تماما كما أخبرك الطبيب أو الصيدلي. إن لم تكن متأكدا من كيفية الاستخدام ،ارجع إلى الطبيب أو الصيدلي.</p><p dir="RTL"><strong>الاستخدام بعد الجراحة</strong></p><p dir="RTL">الجرعة الموصى بها للبالغين وكبار السن: هي مقدار قطرة أو قطرتين في كيس الملتحمة للعين أو العينين المصابة أربع مرات يومياً.</p><p dir="RTL">يبدأ العلاج بدواء لوتماكس عادة بعد 24 ساعة من إجراء الجراحة ويستمر لأسبوعين.</p><p dir="RTL"><strong>الاستخدام في الأمراض الأخرى التي تستجيب لمادة الستيرويد</strong></p><p dir="RTL">قم بوضع قطرة واحدة أو قطرتين من لوتماكس في كيس الملتحمة للعين أو العينين المصابة أربع مرات يومياً. كما يجوز زيادة الجرعة إلى قطرة واحدة كل ساعة خلال المرحلة الأولى من العلاج في الأسبوع الأول. كما ينبغي على المريض أن يقوم بزيارة الطبيب مجدداً في حال لم تتحسن حالته خلال يومين من بداية العلاج (يرجى الإطلاع على &quot;التحذيرات والإحتياطات&quot;).</p><p dir="RTL"><strong>الجرعة المقررة للبالغين</strong></p><p dir="RTL">&middot;&nbsp;قم برج عبوة لوتماكس جيدا قبل الاستخدام.</p><p dir="RTL">&middot;&nbsp;قم بالنظر الى أعلى وبرفق اسحب الجفن السفلي للعين المصابة الى الأسفل.</p><p dir="RTL">&middot;&nbsp;قم بوضع قطرة أو قطرتين من دواء<strong> </strong>لوتماكس بالمنطقة الموجودة بين مقلة وجفن العين أربع مرات يوميا أو حسب تعليمات الطبيب.</p><p dir="RTL">&middot;&nbsp;لا تدع طرف القطارة يلامس أي سطح، مما قد يؤدي إلى تلوث الدواء.</p><p dir="RTL">&middot;&nbsp;يجب غلق الزجاجة مباشرة بعد الاستخدام.</p><p dir="RTL">&middot;&nbsp;سيخبرك طبيبك إلى متى يستمر علاجك بدواء لوتماكس.</p><p dir="RTL">&middot;&nbsp;لا تتوقف عن العلاج دون التحدث مع طبيبك.</p><p dir="RTL"><strong>الاستخدام من قبل الأطفال والمراهقين</strong></p><p dir="RTL">- يجب عدم استخدام لوتماكس من قبل الأطفال والمراهقين حتى يتوفر المزيد من البيانات.</p><p dir="RTL"><strong>إذا استخدمت لوتماكس أكثر من اللازم</strong></p><p dir="RTL">يجب عليك إخبار الطبيب أو الصيدلي.</p><p dir="RTL"><strong>إذا نسيت أن تستخدم لوتماكس</strong></p><p dir="RTL">-&nbsp;لا تقم بأخذ ضعف الجرعة لتعويض الجرعة المنسية.</p><p dir="RTL">-&nbsp;انتظر حتى موعد الجرعة التالية ثم استمر كما كان من قبل.</p><p dir="RTL"><strong>إذا توقفت عن استخدام لوتماكس</strong></p><p dir="RTL">-&nbsp;دائماً استخدم هذا الدواء تماما كما وصف لك الطبيب. لا تقم بالتوقف عن العلاج دون التحدث مع طبيبك.</p><p dir="RTL">-&nbsp;في حال كانت لديك أي أسئلة أخرى حول طريقة استخدام هذا الدواء، استشر الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب في حدوث أعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p dir="RTL">تشمل الآثار الجانبية للستيرويدات العينية ارتفاع ضغط العين ، والذي قد يترافق مع تلف العصب البصري ، مشاكل في حدة البصر ومجال الرؤية ،</p><p dir="RTL">حدوث إعتام في عدسة العين تحت المحفظة الخلفية ، عدوى العين الثانوية بسبب الجراثيم بما يشمل الهربس البسيط ، وحدوث ثقب بمقلة العين الناتج عن ترقق في القرنية أو غشاء العين الخارجي.</p><p dir="RTL">تضمنت الأثار الجانبية التي حدثت في 5-15٪ من المرضى الذين عولجوا بالمستعلق العيني لوتيبريدنول ايتابونات &nbsp;بتركيز يتراوح من (0.2٪ -0.5٪) في الدراسات السريرية حدوث ضبابية / رؤية غير طبيعية ، والشعور بحرقان عند التقطير ، وتورم الملتحمة ، وإفرازات العين ، وجفاف العين ، والدماع ، والإحساس بوجود جسم غريب في العينين ، وحكة العين ، واحمرار الملتحمة ، وحساسية الضوء. تشمل الأثار الجانبية الأخرى التي تحدث في أقل من 5٪ من المرضى حدوث التهاب الملتحمة ، وتشوهات بالقرنية ، وحُمَامَى الجفن ، والتهاب القرنية والملتحمة ، وتهيج / ألم / عدم راحة العين ، و النتوءات ، والتهاب قزحية العين. كانت بعض هذه الأعراض مشابهة لمرض العين المستبطن قيد الدراسة.</p><p dir="RTL">كما أشارت الدراسات إلى حدوث آثار جانبية غير مرغوب بها بمواضع أخرى غير العين لدى نسبة أقل من 15% من المرضى؛ وشملت هذه الآثار حدوث صداع بالرأس، سيلان الأنف والتهاب اللوزتين.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">ينبغي على أخصائي الرعاية الصحية أن يقوموا بالإبلاغ عن الأعراض الجانبية المشتبه بها.</p><p dir="RTL"><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>دول الخليج العربي الأخرى:</strong></p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;يتم تخزين الدواء تحت درجة حرارة 30 درجة مئوية. لا ينبغي تجميده ويجب إبقاؤه بعيداً عن متناول الأطفال.</p><p dir="RTL">-&nbsp;يتم التخلص من العبوة بعد مرور 28 يوم من فتح العبوة لأول مرة.</p><p dir="RTL"><strong>لا ينبغي استعمال الدواء إذا كان شريط السلامة اللاصق المطبوع غير محكم الغلق</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة : لوتيبريدنول ايتابونات، يحتوي كل مل على 5 ملجم (0.5%) من لوتيبريدنول ايتابونات.</p><p dir="RTL">-&nbsp;المكونات الأخرى: ثنائي صوديوم اديتات &ndash; الجليسرول &ndash; بوفيدون &ndash; ماء منقى &ndash; تيلوكسابول.</p><p dir="RTL">- يتم إضافة كلورايد البنزالكونيوم (0,01%) كمادة حافظة.</p><p dir="RTL">-&nbsp;يتم إضافة هيدروكسيد الصوديوم و/أو حمض الهيدروكلوريك لضبط درجة الحموضة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- لوتماكس هو قطرات للعين، مستعلق ذو لون أبيض كالحليب.</p><p dir="RTL">- تتم تعبئة لوتماكس في زجاجات تحتوي على 5 مل من الدواء.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة بوش آند لومب إنكوربوريتد.</p><p dir="RTL">33637 تامبا، فلوريدا.</p><p>الولايات المتحدة الأمريكية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LOTEMAX® 0.5% w/v Eye Drops, Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LOTEMAX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti- inflammatory corticosteroid for ophthalmic use.
The suspension contains 0.5% w/v loteprednol etabonate (5 mg/ml).
Loteprednol etabonate is a white to off-white powder & is represented by the following structural formula:
Mol.Wt. 466.96
Chemical Name: chloromethyl 17α-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxoandrostra-1,4diene- 17-carboxylate
Excipient with known effect: Benzalkonium Chloride (0.01%) For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye-drops, suspension Milky-white
The pH adjusted to 5.5-5.6. The suspension is essentially isotonic with a tonicity of 250 to 310 mOsmol/kg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Steroid Responsive Disease Treatment: Apply one to two drops of LOTEMAX into the conjunctival sac of the affected eye(s) four times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re- evaluated (See PRECAUTIONS).</p><p><u>Post-Operative Inflammation:</u> Apply one to two drops of LOTEMAX into the conjunctival sac of the operated eye(s) four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.</p><p>Pediatric Use:</p><p>Safety and effectiveness in pediatric patients have not been established.</p><p><u>Method of administration</u></p><p>Ocular use</p><p>Shake the bottle vigorously before using the eye drops.</p><p>This product is sterile when packaged. Patients should be advised not to allow the dropper tip to touch any surface, as this may contaminate the suspension. If pain develops, redness, itching or inflammation becomes aggravated, the patient should be advised to consult a physician. As with all ophthalmic preparations containing benzalkonium chloride, patients should be advised not to wear soft contact lenses when using LOTEMAX.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LOTEMAX, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia,and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
LOTEMAX is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation listed in section 6.1 and to other corticosteroids.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>WARNINGS:</strong></p><p>Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Steroids should be used with caution in the presence of glaucoma.Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection.</p><p>Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.</p><p>The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.</p><p>This product contains Benzalkonium Chloride</p><p>PRECAUTIONS:</p><p><strong>General: </strong>For ophthalmic use only. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.</p><p>If signs and symptoms fail to improve after two days, the patient should be re-evaluated.</p><p>If this product is used for 10 days or longer, intraocular pressure should be monitored even though it may be difficult in children and uncooperative patients (see WARNINGS).</p><p>Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since loteprednol etabonate is not detected in plasma following the topical administration of LOTEMAX, it is not expected to affect the pharmacokinetics of systemically administered medicinal products. Numerous concomitant medications were used during clinical studies. These include drugs used in the treatment of underlying diseases (eg, anti-allergy agents) or in a few cases, ocular hypotensive agents. None of the events reported were associated with a deleterious effect of drug combinations, and no drug interactions were noted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Loteprednol etabonate has been shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of meningocele, abnormal left common carotid artery, and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity. The no-observed-effect-level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose). Oral treatment of rats during organogenesis resulted in teratogenicity (absent innominate artery at &ge;5 mg/kg/day doses, and cleft palate and umbilical hernia at &ge;50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with &ge;50 mg/kg/day).</p><p>Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity.</p><p>Loteprednol etabonate was maternally toxic (significantly reduced body weight gain during treatment) when administered to pregnant rats during organogenesis at doses of &ge;5 mg/kg/day.</p><p>Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased growth and survival, and retarded development in the offspring during lactation; the NOEL for these effects was 5 mg/kg/day. Loteprednol etabonate had no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period.</p><p>For loteprednol etabonate no clinical data on exposed pregnancies are available. Studies in animals have shown reproductive toxicity when loteprednol etabonate was administered orally at 35 times the maximum clinical daily dose. The potential risk for humans is unknown.</p><p><strong><u>Breastfeeding</u></strong></p><p>It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.</p><p><strong><u>Carcinogenesis, mutagenesis, impairment of fertility</u></strong></p><p>Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic in vitro in the Meas test, the mouse lymphoma tk assay or in a chromosome aberration test in human lymphocytes or in vivo in the single dose mouse micronucleus assay. Treatment of male and female rats up to 50 mg/kg/day and 25 mg/kg/day of loteprednol etabonate, respectively, (600 and 300 times the maximum clinical dose, respectively) prior to and during mating did not impair fertility in either gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been performed on the ability to drive and use machines after instillation. Based on the pharmacology of the drug no effect is expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects,</p><p>posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.</p><p>Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2%-0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia. Other ocular adverse reactions occurring in less than 5% of patients include conjunctivitis, corneal abnormalities, eyelid erythema, keratoconjunctivitis, ocular irritation/pain/discomfort, papillae, and uveitis. Some of these events were similar to the underlying ocular disease being studied.</p><p>Non-ocular adverse reactions occurred in less than 15% of patients. These include headache, rhinitis and pharyngitis.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Undesirable effects</strong></p></td><td style="vertical-align:top"><p><strong>Incidence</strong></p></td></tr><tr><td style="vertical-align:top"><p><em><u>Ocular adverse reactions:</u></em></p><p>Elevation of intraocular pressure</p><p>Abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.</p><p><em><u>Other ocular adverse reactions:</u></em></p><p>Conjunctivitis, corneal abnormalities, eyelid erythema,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; keratoconjunctivitis,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ocular irritation/pain/discomfort, papillae, and uveitis.</p></td><td style="vertical-align:top"><p>2% of the patients treated for 28 days or longer in summation of randomized controlled studies</p><p>5-15% of the patients treated with loteprednol etabonate ophthalmic suspension (0.2%-0.5%) in clinical studies</p><p>Less than 5% of the patients treated in clinical studies</p></td></tr><tr><td style="vertical-align:top"><p><em><u>Non-ocular adverse reactions:</u></em></p><p>Headache, rhinitis and pharyngitis.</p></td><td style="vertical-align:top"><p>Less than 15% of the patients treated in clinical studies</p></td></tr></tbody></table><p>In a summation of controlled, randomized studies of individuals treated for 28 days or longer with loteprednol etabonate, the incidence of significant elevation of intraocular pressure (&ge;10 mmHg) was 2% (15/901) among patients receiving loteprednol etabonate, 7% (11/164) among patients receiving 1% prednisolone acetate and 0.5% (3/583) among patients receiving placebo.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;SFDA Call Center: 19999</p><p>-&nbsp;E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;Website: https://ade.sfda.gov.sa/</p><p><strong>Other GCC States:</strong></p><p>-&nbsp;Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported. Acute overdosage is unlikely to occur via the ophthalmic route.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Corticosteroid, ATC code: S01BA14</p><p><u>Mechanism of action</u></p><p>Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or</p><p>slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A, inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<sub>2</sub>.</p><p><u>Pharmacodynamic effect</u></p><p>Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20 position ketone group is absent. It is highly lipid soluble which enhances its penetration into cells. Loteprednol etabonate is synthetized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon <em>in vivo </em>and <em>in vitro </em>preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites.</p><p><u>Clinical efficacy and safety</u></p><p>Post-Operative Inflammation: Placebo controlled clinical studies demonstrated that LOTEMAX is effective for the treatment of anterior chamber inflammation as measured by cell and flare.</p><p>Giant Papillary Conjunctivitis: Placebo controlled clinical studies demonstrated that LOTEMAX was effective in reducing the signs and symptoms of giant papillary conjunctivitis after 1 week of treatment and continuing for up to 6 weeks while on treatment.</p><p>Seasonal Allergic Conjunctivitis: A placebo-controlled clinical study demonstrated that LOTEMAX was effective in reducing the signs and symptoms of allergic conjunctivitis during peak periods of pollen exposure.</p><p>Uveitis: Controlled clinical studies of patients with uveitis demonstrated that LOTEMAX was less effective than prednisolone acetate 1%. Overall, 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with 1% prednisolone acetate. The incidence of patients with clinically significant increases in IOP (&ge;10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%.</p><p>LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (&ge;10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication.</p><p><u>Paediatric population</u></p><p>Safety and effectiveness in paediatric patients have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Results from a bioavailability study in normal volunteers established that plasma levels of loteprednol etabonate and r<sup>1</sup> cortienic acid etabonate (PJ91), its primary, inactive metabolite, were below the limit of quantitation (1ng/mL) at all sampling times. The results were obtained following the ocular administration of one drop in each eye of 0.5% loteprednol etabonate 8 times daily for 2 days or 4 times daily for 42 days. This study suggests that limited (&lt;1 ng/mL) systemic absorption occurs with LOTEMAX.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Loteprednol etabonate has been shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of meningocele, abnormal left common carotid artery, and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity. The no-observed-effect-level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose). Oral treatment of rats during organogenesis resulted in teratogenicity (absent innominate artery at &ge;5 mg/kg/day doses, and cleft palate and umbilical hernia at &ge;50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with &ge;50 mg/kg/day).</p><p>Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity.</p><p>Loteprednol etabonate was maternally toxic (significantly reduced body weight gain during treatment) when administered to pregnant rats during organogenesis at doses of &ge;5 mg/kg/day.</p><p>Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased growth and survival, and retarded development in the offspring during lactation; the NOEL for these effects was 5 mg/kg/day. Loteprednol etabonate had no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium Edetate</p><p>Glycerol Povidone</p><p>Purified Water</p><p>Tyloxapol</p><p>Hydrochloric Acid (pH adjuster)</p><p>Sodium Hydroxide (pH adjuster)</p><p>Benzalkonium Chloride</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of incompatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years (unopened).
Discard any unused contents 28 days after first opening the bottle.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store upright<s> </s>Store below 30&deg;C. DO NOT FREEZE. KEEP OUT OF REACH OF CHILDREN.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LOTEMAX is available in a plastic bottle with a controlled drop tip in the following size: 5 mL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store the container in an upright position.</p><p><strong>DO NOT USE IF NECKBAND IMPRINTED WITH &quot;Protective Seal&quot; AND YELLOW *** IS NOT INTACT</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bausch and Lomb Incorporated
Tampa, Florida 33637
USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>